Reports Wed Jul 29Before openConfirmed
Biogen reports before the bell with Leqembi momentum on the line against shrinking MS royalties, the test of whether its Alzheimer's bet can actually move the needle on growth.
![BIIB logo]()
Biogen :
BIIB
BIIB
Stock Data
$207.94
$1.66 (0.80%)
Asset Type
Common Stock
Exchange
NASDAQ
Currency
USD
Country
USA
Sector
HEALTHCARE
Industry
DRUG MANUFACTURERS - GENERAL
Biogen Inc. is a pioneer in the biotechnology sector, focusing on developing treatments for neurological and neurodegenerative conditions. With a global presence, Biogen offers a range of therapies for diseases such as multiple sclerosis, spinal muscular atrophy, and Alzheimer's. Its portfolio includes well-known drugs like TECFIDERA, SPINRAZA, and ADUHELM. Additionally, Biogen is involved in creating biosimilars, which are essentially generic versions of biologic drugs, expanding its impact on healthcare. Founded in 1978 and based in Cambridge, Massachusetts, Biogen continues to push the boundaries of medicine through innovation and partnerships.
Latest Activity
Q2 2026
EPS
$3.60
est $2.07+73.6%
Revenue
$2.74B
est $2.46B+11.4%
Biogen's growth portfolio revenue finally surpassed its legacy MS business, propelled by a massive 73% EPS beat and momentum from the Apellis acquisition, prompting a $0.60 full-year guidance raise.
All Biogen Articles
607 Articles
